Success Metrics

Clinical Success Rate
66.7%

Based on 4 completed trials

Completion Rate
67%(4/6)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_4
1
17%
Ph phase_1
3
50%
Ph phase_3
1
17%
Ph phase_2
1
17%

Phase Distribution

3

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
1(16.7%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(4)
Terminated(2)

Detailed Status

Completed4
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
66.7%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (50.0%)
Phase 21 (16.7%)
Phase 31 (16.7%)
Phase 41 (16.7%)

Trials by Status

completed467%
terminated233%

Recent Activity

0 active trials
Showing 5 of 6
terminatedphase_2

Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD

NCT02255227
completedphase_1

Evaluation of Pneumococcal Vaccine Formulations in Elderly

NCT00756067
completedphase_1

Evaluation of Pneumococcal Vaccine Formulations in Young Adults

NCT00707798
completedphase_1

Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population

NCT00327665
completedphase_3

Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

NCT00594347
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT02255227Phase 2

Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBD

Terminated
NCT00756067Phase 1

Evaluation of Pneumococcal Vaccine Formulations in Elderly

Completed
NCT00707798Phase 1

Evaluation of Pneumococcal Vaccine Formulations in Young Adults

Completed
NCT00327665Phase 1

Study to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in the Elderly Population

Completed
NCT00594347Phase 3

Immunogenicity and Safety of a Booster Dose of Pneumo 23® in 12 to 18 Months-Old Children Primed With Prevnar

Completed
NCT00368186Phase 4

Immunogenicity and Safety Study of Pneumococcal 7-Valent Conjugate Vaccine in Sickle Cell Disease Infants.

Terminated

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6